Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors by GAY, Francesca Maria et al.
iris-AperTO 
University of Turin’s Institutional Research Information System and Open Access Institutional 
Repository 
 
 
 
 
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is 
posted here by agreement between Elsevier and the University of Turin.  
Changes resulting from the publishing process - such as editing, corrections, structural 
formatting, and other quality control mechanisms - may not be reflected in this version 
of the text. The definitive version of the text was subsequently published in: 
 
 
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 17 (8), 2017, pp: 471-478 
DOI: 10.1016/j.clml.2017.06.014 
 
 
 
You may download, copy and otherwise use the AAM for non-commercial purposes provided that 
your license is limited by the following restrictions: 
(1) You may use this AAM for non-commercial purposes only under the terms of the CC-BY-NC-
ND license.  
(2) The integrity of the work and identification of the author, copyright owner, and publisher must 
be preserved in any copy.  
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND license 
(http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en): 
 
https://doi.org/10.1016/j.clml.2017.06.014 
 
 
When citing, please refer to the published version. 
 
 
Link to this full text: 
http://hdl.handle.net/2318/1649093      
This full text was downloaded from iris-Aperto: https://iris.unito.it/  
Accepted Manuscript
Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors
Francesca Gay, Mattia D’Agostino, Luisa Giaccone, Mariella Genuardi, Moreno
Festuccia, Mario Boccadoro, Benedetto Bruno
PII: S2152-2650(17)30709-7
DOI: 10.1016/j.clml.2017.06.014
Reference: CLML 948
To appear in: Clinical Lymphoma, Myeloma and Leukemia
Received Date: 24 April 2017
Accepted Date: 8 June 2017
Please cite this article as: Gay F, D’Agostino M, Giaccone L, Genuardi M, Festuccia M, Boccadoro M,
Bruno B, Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors, Clinical Lymphoma,
Myeloma and Leukemia (2017), doi: 10.1016/j.clml.2017.06.014.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Immuno-oncologic approaches: CAR-T cells and checkpoint inhibitors 
 
 
Francesca Gay,1 Mattia D’Agostino,1 Luisa Giaccone,2 Mariella Genuardi,1 Moreno Festuccia,2 Mario 
Boccadoro,1 Benedetto Bruno.2 
 
 
 
1 Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città 
della Salute e della Scienza di Torino, Torino, Italy; 2 Department of Molecular Biotechnology and Health 
Sciences, University of Turin, Struttura Semplice Dipartimentale Allogeneic Stem Cell Transplant, Azienda 
Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Italy; 
 
 
Corresponding author: Francesca Gay, Francesca Gay, Azienda Ospedaliero-Universitaria Città della 
Salute e della scienza di Torino, Via Genova, 3-10126 Torino, Italy; e-mail: fgay@cittadellasalute.to.it 
 
Disclosure: Francesca Gay has served on the advisory of Takeda, Seattle Genetics, Roche and received 
honoraria from Takeda, Amgen, Celgene, Janssen, BMS. The other authors declare no potential conflicts. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Abstract (words-max 250: 250) 
Advances in understanding the myeloma biology have shown that disease progression is not only the 
consequence of intrinsic tumor changes but also of interactions between the tumor and the microenvironment 
in which the cancer grows. Immune system is an important component of the tumor microenvironment in 
myeloma, and acting on immune system is an appealing new treatment strategy. There are 2 ways to act 
towards immune cells and boost anti-tumor immunity: 1) to increase antitumor activity (acting on T and NK 
cytotoxic cells); and 2) to reduce immunosuppression (acting on myeloid-derived stem-cells and T 
regulatory cells). Checkpoint inhibitors and adoptive cell therapy (ACT) are two of the main actors, together 
with monoclonal antibodies and immunomodulatory agents, in the immune-oncologic approach. The aim of 
checkpoint inhibitors is to release the brakes that block the action of the immune system against the tumor. 
Anti-programmer death-1 (PD1) and PD1-Ligand, as well as anti-CTLA4 and KIR are currently under 
evaluation, as single agents or in combination, with so far the best results achieved with combination of anti-
PD1 and immunomodulatory agents. The aim of ACT is to create an immune effector specific against the 
tumor. Preliminary results on chimeric antigen receptor (CAR) T cells, first against CD19, and more recently 
against B cell maturation antigen, have shown to induce durable responses in heavily pretreated patients. 
This review will focus on the most recent clinical results available on the use of checkpoint inhibitors and 
CAR-T cells in myeloma, in the context of the new immune-oncologic approach. 
 
Key words: check-point inhibitors, CAR-T cells, immune-oncology 
Text word count:  3959 
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Introduction 
There have been significant advances in the understanding of the biology of multiple myeloma (MM) in 
recent years. In the classical view of the pathogenesis of MM, an initiating hit is necessary to immortalize a 
myeloma-propagating cell. This cell then acquires additional genetic hits over time, mediated by 
translocation, loss of heterozygosity, gene amplification, mutation, or epigenetic changes, which further 
deregulate the behavior of the MM-propagating cell, leading step by step to the well-known MM features.1 
Many of the genes and pathways mediating this transformation process have now been characterized. 
Nevertheless, disease progression is not only the consequence of intrinsic tumor changes. Interactions 
between the tumor and the microenvironment in which the cancer grows, play an essential role,2 and the 
focus of studies has shifted from the disease itself alone to the disease in the context of the 
microenvironment where the tumor grows. Immune system is an important component of the tumor 
microenvironment in MM, as well as in many other cancers, and is the focus of the immune-oncology 
approach.  
Rationale for immune-oncology 
The immune system can potentially recognize and reject the tumor. Tumor cells can express aberrant 
antigens i.e. molecules expressed in tumor cells, but not in normal cells. These can be normal cellular 
proteins that are abnormally expressed as a result of genetic mutations, quantitative differences in 
expression, or differences in posttranslational modifications.3 In tumor types that have a well-documented 
viral origin, viral proteins can also serve as tumor antigens.4,5 Tumor antigens are first recognized by the 
innate immune system subsets, among which natural killer (NK) cells have the capability to kill tumor cells. 
Macrophages and dendritic cells then uptake and process fragments from these destructed cells, secrete 
inflammatory cytokines and present tumor cell-derived molecules to T and B cells. Activation of T- and B-
cells leads to the expansion of tumor-specific cell clones and antibodies. Moreover, adaptive immunity 
subsets produce additional cytokines that further promote activation of innate immunity. The final goal of the 
adaptive immune system is to the eliminate the remaining tumor cells and to generate immune memory 
against specific tumor components, thus preventing tumor recurrence.6  
This process can result in different outcomes. A highly immunogenic tumor in a highly immunocompetent 
individual can eliminate the arising tumor. In a less immunocompetent individual and/or in case of less 
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immunogenic tumor, there can be an incomplete elimination leading to the survival of some cancer cells that 
nevertheless remain under immunosurveillance. This phase could be at some point disturbed by changes in 
the tumor that allow it to avoid immunosurveillance, or changes in the immune system that weaken its 
capacity to keep the tumor under control, leading to tumor escape.7 The escape phase of immunosurveillance 
is characterized by an increase in immunosuppressive cells, such as regulatory T cells (Tregs) and myeloid-
derived suppressor cells (MDSC). Immunosuppressive cytokines derived from Tregs, MDSC and tumor cells 
themselves can hamper the effector function of T cells.8–10 
MM is characterized by a profound immune dysfunction affecting both the innate and adaptive immune 
system.11 Antigen cross-presentation is the dominant mechanism of tumor antigen priming12 and as a 
consequence, the functional status of antigen presenting cells (APCs) is crucial. Dendritic cells from MM 
patients are functionally impaired and express/produce lower levels of critical molecules that can initiate the 
immune response (such us interleukin 12 (IL-12), HLA-DR, CD40, CD86, and CD80).13,14 Regulatory T 
cells may exert immunosuppression by several mechanisms, including production of anti-inflammatory 
cytokines (IL-10 and TGFb), and reduction in IL-2.15 MDSCs inhibit T cells by producing arginase-1, 
reactive oxygen species, and nitric oxide.16  MM cells themselves play an important role in maintaining 
immunosuppression. As an example, they can produce TGFβ and express PDL-1, both leading to T cells 
inhibition. Taken together, all these mechanisms suggest a complex interaction between MM cells and the 
immune system, with several possible targets for the immune-oncologic approach.  
Immune-oncologic approach in MM 
Immune therapy can be directed against the tumor itself or towards immune cells. There are 2 strategies to 
act towards immune cells and boost anti-tumor immunity: one consists in increasing antitumor activity 
(acting on T and NK cytotoxic cells), the other one in reducing immunosuppression (acting on MDSC and 
Tregs). Treatment approaches include monoclonal antibodies (mAbs) targeting surface molecules present on 
MM cells, mAbs targeting checkpoint inhibitors on immune cells/tumor cells, immunomodulation, vaccines 
and adoptive cell therapy (ACT). Several targets, however, are expressed on both MM cells and immune 
cells, thus leading to complex mechanism of actions.  
The review focuses on checkpoint inhibitors and chimeric antigen receptor (CAR)-T cells based ACT 
(Figure 1). To contextualize the role of checkpoint inhibitors and ACT in the immune-oncology approach, 
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we will provide a brief summary of the main mechanisms by which mAbs targeting surface molecules 
present on the MM cells, immunomodulation and vaccines act on the immune system .  
Elotuzumab is a mAb targeting SLAMF7 (also known as CS-1), present on both MM cells and NK cells. It 
causes MM cell death via a dual mechanism of action. The Fab portion of Elotuzumab binds SLAM F7 on 
MM cells, the Fc portion binds CD16 on NK. This interaction triggers NK activation, release of cytotoxic 
granules and MM cell killing.17,18 This agent did not show efficacy as single agent, but proved to be effective 
in combination with both lenalidomide and bortezomib.19,20  
Daratumumab is a human IgG1 mAb that targets CD38-expressing cells. Daratumumab binding to CD38 
induces tumor cell death through direct and indirect mechanisms. It can induce apoptosis via CD38 cross-
linking and have an anti-tumor effect mediated by the activation of complement dependent cytotoxicity, 
antibody dependent cell phagocytosis and antibody dependent cell cytotoxicity. CD38 is also expressed on 
highly immunosuppressive Treg and Breg cells, as well as on MDSC; daratumumab eliminates these highly 
immunosuppressive cells, thus stimulating cytotoxic T cell mediated antitumor effects.21–25 Daratumumab 
showed efficacy as single agent in heavily pre-treated patients,26,27 as well as in combination with bortezomib 
and with lenalidomide.28,29  
Immunomodulatory drugs are of particular interest in combination with both mAbs and checkpoint 
inhibitors. In particular, lenalidomide enhances immunogenicity by inducing T-cell activation through 
increased tyrosine kinase activity of the CD28 receptor, downregulation of CD45RA on T cells, and 
downregulation of SOCS1 on stromal cells in the microenvironment.30–32 The aim of vaccines is to increase 
the frequency of antigen-specific T cells or antibodies. Vaccination approaches in MM include idiotype 
vaccines, dendritic cell-based and GM-CSF-based vaccines and cancer testis antigens vaccines. 
Nevertheless, the main limitations to the efficacy of this approach is the intrinsic immune dysfunction 
associated with the tumor itself, especially in the presence of high disease burden, and the use in a 
therapeutic setting and not prevention setting as for anti-pathogen vaccines.33 
 
Checkpoint blockade therapy 
Inhibitory molecules known as “immune checkpoint proteins” are expressed by a variety of immune cells 
(e.g. T and NK cells) to control the intensity and duration of immune responses, playing a pivotal role in the 
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induction of peripheral self-tolerance and the limitation of tissue damage.34 The avoidance of immune-
mediated destruction is a well-known hallmark of cancer biology,35 as discussed above. MM cells like many 
other cancer cells exploit this physiologic mechanism to escape the surveillance mediated by the immune 
system. The main immune checkpoint pathways targeted in MM are cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA4), programmed cell death protein 1 (PD1), programmed cell death ligand 1 (PD-L1) and 
Killer-cell immunoglobulin-like receptors (KIRs). Clinical results of their inhibition through mAbs in 
myeloma field are summarized in Table 1. 
CTLA-4 
CTLA-4 was the first immune checkpoint molecule fulfilling the requirements to be clinically targeted in 
cancer.36 CTLA-4 is a fundamental negative regulator of T-cell function and its absence causes immune 
hyperactivation and lethal diffuse lymphocytic infiltration in mice models.37 In T-cells, CTLA-4 antagonizes 
the activating signal mediated by CD28, competing for the same ligand (B7-1) expressed by dendritic cells.38 
Upon the binding of B7-1, CTLA-4 induces in T-cells antigen-specific anergy.39 
In MM patients, CTLA-4 is significantly overexpressed on CD4+ and CD8+ T cells in the bone marrow but 
not in the peripheral blood, compared to healthy donors.2 This evidence suggests an enhanced T-cell 
unresponsiveness towards MM cells, especially at the tumor site, that can be theoretically reverted by 
CTLA-4 inhibition. Building on this hypothesis and on the clinical success of CTLA-4 inhibition in 
melanoma patients,36 two mAbs targeting CTLA-4 are in clinical development in MM. 
Ipilimumab (IgG1, fully human) has been studied as a single agent in 29 hematologic patients (21% with 
MM) relapsing from allogeneic stem-cell transplantation in order to stimulate the graft-versus-tumor effect 
mediated by effector T-cells in this setting,40 but no objective responses were elicited in MM patients. Due to 
the peculiar mechanism of action, the major risk associated with checkpoint blockade therapy is to induce 
autoimmune-like syndromes, known as immune-related adverse events (IRAEs). This aspect is very relevant 
in the allogeneic setting, with an additional risk of graft-versus-host disease (GvHD). In this trial, 
ipilimumab did not induce grade 3-4 GvHD or graft rejection. IRAEs were registered in 4 patients (1 grade 3 
polyarthritis, 1 grade 2 hyperthyroidism, 1 recurrent grade 4 pneumonitis and 1 obstructive defect with no 
infectious cause identified), however none of them had MM. 
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Trials in MM patients are currently evaluating ipilimumab-based combinations (NCT01592370), comparing 
ipilimumab with another checkpoint inhibitor acting on a different target (nivolumab) in the allogeneic SCT 
setting (NCT01822509) and combining ipilimumab with nivolumab in the autologous SCT setting 
(NCT02681302).  
Tremelimumab (IgG2, fully human) is another CTLA-4 targeting mAb. Although no clinical data are yet 
available in MM patients, a trial involving tremelimumab-combination therapy with another checkpoint 
inhibitor acting towards a different target (durvalumumab) after autologous SCT is currently planned 
(NCT02716805). 
PD-1/PD-L1 
The immune checkpoint pathway that produced the most promising preclinical and clinical data in MM is 
based on the interaction between two transmembrane proteins: PD1 and PD-L1. 41PD-1, differently from 
CTLA-4, is expressed not only by T cells, but also by NK cells, B cells and other immune cell  subsets, 
playing a pivotal role in the balance between immune system activation and self-tolerance.42 Differently 
from CTLA-4, PD-1 deficient mice develop lupus-like systemic inflammation,43 suggesting that CTLA-4 
and PD-1/PD-L1 axis may work in slightly different aspects of immune regulation. Table 2 summarizes the 
main similarities and differences in CTLA-4 and PD-1. 
PD-L1 is expressed by antigen-presenting cells and other cell subtypes, delivering inhibitory signals through 
the engagement of PD-1.44 Normal plasma cells do not express PD-L1, while PD-L1 is expressed on the 
surface of MM cell lines and neoplastic plasma cells isolated from MM patients.45,46  
PD-1 may bind another ligand besides PD-L1, known as PD-L2. PDL2 expression could be detected in the 
microenvironment of solid tumors, however it does not seem to be a key inhibitor of T-cell function at the 
tumor site.47 
There is evidence that blocking PD-1 and/or PD-L1 through mAbs in order to prevent their interaction can 
enhance myeloma-cell killing by T and NK-cells in vitro.48 Moreover, in a MM mouse model, Hallett and 
colleagues demonstrated that PD-L1 on MM cells engaging PD-1 expressed by T-cells and NK cells, 
decrease their cytotoxic function, proliferation, and cytokine production, thus leading to a functionally 
exhausted state of these cells.46 
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Based on these biologic data and on the success of mAbs targeting PD-1 in solid tumors49 and Hodgkin’s 
lymphoma,50 several mAbs targeting this pathway are being evaluated in MM. 
Nivolumab is a fully human IgGk mAb targeting PD-1. A phase Ib trial evaluated its safety and efficacy as 
single agent in hematologic patients affected by several malignancies, among which 27 with relapsed and/or 
refractory MM (RRMM) patients. Unfortunately, in this subgroup of patients, no objective responses were 
reported.51 Building on pharmacokinetic data demonstrating a long-lasting binding of Nivolumab to its 
receptor, Funt and colleagues recently reported on next line of therapy after nivolumab infusion in 8 RRMM 
patients.52 An unusually low rate of progressive disease was reported in this highly refractory patient 
population and interestingly a patient who relapsed with an isolated plasmacytoma received only 
radiotherapy and then resumed Nivolumab treatment with a progression-free period of more than 2 years. 
Several ongoing trials are evaluating Nivolumab in combination with Daratumumab ± Pomalidomide-
Dexamethasone (NCT01592370), Pomalidomide-Dexamethasone ± Elotuzumab (NCT02726581) and with 
anti-CTLA4 mAbs after autologous (NCT02681302) and allogeneic (NCT01822509) stem cell 
transplantation. 
Pembrolizumab is a humanized anti-PD1 IgGk mAb. It is probably the anti-PD1 mAb evaluated in the 
greatest number of malignancy types. Data on monotherapy in MM field are lacking, however 
pembrolizumab has been tested in combination with dexamethasone and immunomodulatory agents in 
RRMM patients. A phase I study in 40 RRMM patients failing at least 2 previous therapeutic lines evaluated 
safety and efficacy of Pembrolizumab added to Lenalidomide-Dexamethasone backbone treatment .53 The 
MTD for Pembrolizumab was 200 mg every 21 days and the overall response rate (ORR) was 50%. Of note, 
responses were also elicited in lenalidomide-refractory patients, suggesting that pembrolizumab and 
lenalidomide could act synergically also in patients refractory to immunomodulators alone. Safety profile 
was acceptable, and hematologic toxicities (thrombocytopenia 41%, neutropenia 37%) were the most 
common treatment-related adverse events . Of note, IRAEs were rare and the most frequent non hematologic 
toxicity was mild diarrhea (28%, all cases grade ≤ 2). A phase III randomized trial evaluating first-line 
treatment with lenalidomide-dexamethasone ± pembrolizumab in transplant ineligible MM patients 
(NCT02579863) is currently ongoing. 
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A phase II trial in 48 lenalidomide-refractory RRMM patients evaluated pembrolizumab in combination with 
pomalidomide and dexamethasone.54 Besides lenalidomide, 80% of enrolled patients were also refractory to 
a proteasome inhibitor.  The overall response rate (ORR) was 56% and responding patients had a median 
duration of response of more than 6 months. Interestingly, double-refractory patients had a superimposable 
ORR (55%). IRAEs reported in this trial were interstitial pneumonitis (13%), hypothyroidism (10%), hepatic 
cytolysis (6%), adrenal insufficiency (4%) and vitiligo (2%). Additional data will come from a phase III trial 
in RRMM patients evaluating pomalidomide-dexamethasone ± pembrolizumab (NCT02576977) that is 
currently enrolling patients. 
PD-1 inhibition in MM is in advanced clinical development, with 2 phase III studies underway. However, 
little is known about targeting its cognate receptor, PD-L1, and about the clinical differences between these 
approaches.55 Durvalumab (MEDI-4736) and Atezolizumab (MPDL3280) are being used in phase I trials in 
MM patients in different settings and with different combinations (Table 1), however no data are available 
yet.  
Killer-cell immunoglobulin-like receptor 
Killer-cell immunoglobulin-like receptors (KIRs) are key regulators of NK cell cytotoxic function. Inhibitory 
and activating KIRs regulate NK cells through the recognition of major histocompatibility class I molecules 
on target cells.56 NK cells harvested from MM patients express inhibitory KIRs,57 moreover malignant 
plasma cells express their cognate surface ligands,58 like major histocompatibility complex (MHC) class 1 
and related proteins. Nijhof and colleagues demonstrated that blocking inhibitory KIRs on NK cells in vitro 
improves daratumumab-induced anti-myeloma activity and this effect was particularly evident when 
lenalidomide was added.59 
Based on this rationale, IPH2101, a human IgG4 mAb targeting KIR2D receptors, has been evaluated in MM 
patients. In a phase I trial, 32 RRMM patients treated with IPH2101 monotherapy  did not show any 
objective responses, however safety was very good with no dose limiting toxicities.57 The lack of single-
agent activity was confirmed also in the smoldering MM setting by a phase II trial.60 A phase I trial 
evaluated the combination of IPH2101 with lenalidomide in RRMM patients.61 Safety profile was acceptable 
and objective responses were reported in 5 out of 15 enrolled patients. Nevertheless, the small number of 
patients and the exclusion of lenalidomide-refractory patients make it difficult to draw conclusions on the 
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efficacy of IPH2101 in the context of immunomodulatory pre-treated patients. 
Another mAb targeting KIRs (Lirilumab) is under development. Combinations study with elotuzumab 
(NCT02252263) and nivolumab (NCT01592370) are currently ongoing. 
 
CAR-T based ACT 
CAR-T cells are autologous or allogeneic T cells genetically engineered to express a chimeric antigen 
receptor specific for a tumor-associated antigen expressed on the neoplastic cell surface. CARs are also 
"equipped" with co-stimulatory domains, which enhance activation and function of CAR-T cells, and 
promote their proliferation and cytokine release.62 CAR-T cells have both advantages and limitations. They 
are not restricted by patient HLA. However, selecting appropriate antigens is crucial to prevent on-target off-
tumor toxicity. Many potential targets have a broad expression on normal cells and tissues.63 Major clinical 
trials have so far employed CAR-T cells that greatly differed in both targeted-antigens and co-stimulatory 
domains.  
CAR-T cells directed against CD19 initially showed a dramatic potential in acute lymphoblastic leukemia 
and chronic lymphocytic leukemia.64–66 Even though CD19 expression is not usually associated with MM 
and it is not considered a therapeutic target,67 some studies identified its expression on a putative minor MM 
stem cell subset68 that may partly be responsible for disease recurrence. Despite being hotly debated, the 
potential existence of a CD19+ MM stem cell formed the rational for conducting clinical trials with specific 
CAR against CD19.69 Garfall et al. initially described one patient treated with anti-CD19 CAR- T cells 
(CTL019).69 The patient underwent CTL019 infusion after a standard autograft. Following cell infusion, no 
fever or other signs of cytokine release syndrome (CRS) were noted and, importantly, CTL019 cells were 
detected in both blood and bone marrow for up to several days after the infusion. The patient started 
lenalidomide maintenance 3 months later. Complete response (CR) was still observed at one year of follow-
up. It is remarkable that the response was achieved despite the absence of CD19 expression on 99.95% of 
plasma cells. An update of this clinical trial on a series of 12 patients was reported at American Society of 
Hematology (ASH) meeting in December 2016.70 Overall, 10 out of 12 patients enrolled were infused with 
CTL019 12–14 days after high-dose melphalan and an autograft. Six patients showed very good partial 
response (VGPR), 2 partial response (PR), 2 progressive disease (PD). Of note, only minor adverse effects 
were reported.  
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More recently, the B cell maturation antigen (BCMA) has drawn increasing attention as a CAR target in 
MM. BCMA is a cell surface protein involved in the differentiation and maturation of B cells into plasma-
cells. However, BCMA is highly expressed also on MM cells. Ali et al reported on a phase I study with an 
anti-BCMA-CAR with a CD28 co-stimulatory molecule.71 Twelve patients received escalating doses of 
CAR-T cells at 0.3, 1, 3, or 9 × 106/kg. All patients were immune-suppressed with cyclophosphamide and 
fludarabine prior to CAR-T cells infusions. Responses included stringent CR (n=1), VGPR (n=2), PR (n=1), 
and SD (n=8). Both best responses and side effects occurred in the highest-dose patients. Only one single 
patient has so far been reported to relapse in the marrow with BCMA-negative MM clones.71 Two other 
BCMA specific CAR-T cells are currently being investigated in clinical trials. Preliminary findings were 
presented at the 2016 ASH meeting by the University of Pennsylvania group.72 In a phase I dose-escalation 
study, with a second generation 4-1BB-CD3ζ anti- BCMA-CAR-T cells, 6 patients received split dose 
infusions, 10% on day 0, 30% on day 1, and 60% on day 2. Overall, 5 patients developed CRS toxicity; 2 
patients required anti IL-6 treatment with tocilizumab. Interestingly, even though these 2 patients had 
received only 40% of the planned CAR-T cell dose, they achieved a remarkable anti-tumor response with a 
stringent CR and a VGPR, respectively. Five months after the last infusion, the patient who achieved VGPR 
progressed with a concomitant reduction of circulating CAR-T cells. Of note, BCMA expression was lost on 
MM cells, which is highly suggestive of antigen escape. Overall, the 4 other patients showed stable disease, 
minimal response, or PD with low expansion of CAR-T cells. Bluebird Bio reported on a cohort of 9 patients 
with RRMM who were infused with second-generation anti-BCMA-CAR-T cells (bb2121) with 4-1BB co-
stimulation.73 Patients received single infusions at different doses (5, 15, or 45×107) after being conditioned 
with cyclophosphamide and fludarabine. Best responses were achieved after the infusion of 15×107 CAR T 
cells: 2 patients showed stringent CR and 1 VGPR.  
CD138 (also known as syndecan 1) is a surface protein expressed on normal and malignant plasma cells,74 
and it binds collagen and fibronectin molecules in the extracellular matrix. Given its high expression on MM 
cells, it has been considered an attractive target. A Chinese group reported their experience with an anti 
CD138 CAR on 5 refractory patients.75 Multiple infusions were well tolerated and only mild fever was 
reported, stable disease was achieved in 4 out of 5 patients. Nevertheless, these are preliminary findings and 
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further confirmation is awaited. Importantly, CD138 is not specifically expressed by MM cells but it is also 
expressed by epithelial cells raising some concerns regarding on-target off-tumor toxicity. Other clinical and 
preclinical studies with CAR-T cells directed against other MM specific targets are in progress. A phase I 
clinical trial of kappa-CD28-CAR-T cells was also conducted at Baylor hospital.76 Two other studies with 
anti CS-1 CAR-T cells (NCT02203825) and anti CD138-CAR-T cells (NCT01886976) are currently 
recruiting patients, and results are eagerly awaited.  
Overall, CAR-T cells are a promising form of immune-therapy in MM. Nonetheless, some relevant concerns 
exist. Antigenic escape is a major limitation of CAR-T cells targeted against a single antigen on MM cells. 
To overcome this phenomenon, targeting two different antigens may improve specificity and efficacy of 
CAR-T cells. Targeted antigens expressed by T-cells themselves and leading to self-killing of CAR-T cells 
are another important issue.77 Other concerns have been raised regarding efficacy, such as depth and duration 
of antitumor effects, and toxicity profile, such as the potential serious systemic toxicities including CRS.78 
Moreover, high tumor burdens may be associated with higher risk of CRS. Anecdotal specific toxicities have 
also been reported. The Pennsylvania group recently published a case report of posterior reversible 
encephalopathy syndrome (PRES) after infusion of anti-BCMA CAR-T cells with worsening neurological 
symptoms despite treatment with tocilizumab and high-dose steroids. However, cyclophosphamide 
administration reversed the syndrome.79 
 
Conclusion 
Advances in the understanding of MM biology and its clinical management have recently led to an increased 
survival rate, reaching up to 8-10 years. Several new agents, with different mechanism of actions and 
different targets, have increased the treatment armamentarium against a complex disease such as MM. These 
agents include chemotherapeutic agents, immunomodulatory drugs and proteasome inhibitors, which are 
currently considered the backbone treatments for MM. Other agents more recently introduced include 
histone deacetylase inhibitors, the so called “small molecules”, monoclonal antibodies, checkpoint inhibitors 
and ACT. Acting on immune system is an appealing new treatment strategy, where checkpoint inhibitors and 
ACT are the main players. Results on checkpoint blockade in MM are promising, but not yet as good as in 
solid tumors. One of the reasons could be the impaired immune function that characterizes immune system 
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of MM patients. The most promising results have been so far achieved in MM in combination with 
immunomodulatory drugs, due to the potential synergistic effect on the immune system. Furthermore,  
checkpoint molecules that are currently clinically exploited are only the tip of the iceberg of the potential 
checkpoint targets expressed by immune-cells. In the near future, data on mAbs targeting lymphocyte 
activation gene 3 protein (LAG-3), T cell immunoglobulin domain and mucin domain 3 (TIM-3), V-domain 
Ig suppressor of T cell activation (VISTA), CD47 and other molecules might be available to researchers. 
The preliminary clinical success of CAR-T cells in lymphoblastic leukemia has reignited the interest in cell 
immunotherapy against MM and this field is now moving forward very rapidly. However, despite durable 
responses in heavily pretreated patients, results are very preliminary and many open questions remain, 
including the definition of the best target, a better understanding of toxicities (e.g. CRS) and efficacy (depth 
of response and its duration). Multiple therapies are currently available for MM and many, new approaches 
will probably be available in the next future.  
Future and ongoing trials are still necessary to shed light on the role of checkpoint inhibitors and CAR-T 
cells in a treatment scenario in continuous evolution.  
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Table 1. Clinical data from key studies exploring mAb-based treatment in RRMM patients 
 
TARGET DRUG COMBINATION STUDY PHASE 
PATIENT POPULATION 
(number of MM patients) 
CLINICAL 
RESULTS 
AVAILABLE 
Y/N 
ORR (%) Reference or NCT 
CTLA-4 
Ipilimumab 
- 1 
Relapsed hematologic 
malignancies after 
allogeneic SCT (6) 
Y 01 Bashey et al40 
Ipilimumab monotherapy vs 
Nivolumab monotherapy 1 
Relapsed hematologic 
malignancies after 
allogeneic SCT (na) 
N - NCT01822509 
Ipilimumab+nivolumab 1b/2a 
Lymphoma and MM 
patients at high risk of 
relapse after ASCT (na) 
N - NCT02681302 
Tremelimumab Durvalumab 1 TE MM patients before and 
after ASCT (24) N - NCT02716805 
PD-1 
Nivolumab 
- 1b RR hematologic 
malignancies (27) Y 0
1
 Lesokhin et al51 
Arm 1: nivolumab monotherapy 
Arm 2: Nivolumab + Ipilimumab / 
Lirilumab 
Arm 3: Daratumumab + Nivolumab ± 
Pomalidomide- Dexamethasone 
1 RRMM ≥ 2 prior therapies (375*) N - NCT01592370 
Arm 1: nivolumab + Pomalidomide- 
Dexamethasone 
Arm 2: Pomalidomide- 
Dexamethasone 
Arm 3: nivolumab + Elotuzumab + 
Pomalidomide- Dexamethasone 
3 RRMM ≥ 2 prior therapies (406*) N - NCT02726581 
Pembrolizumab 
- 1 Smoldering MM (16) N - NCT02603887 
Lenalidomide-dexamethasone 1 RRMM ≥ 2 prior therapies (40) Y 50% Mateos et al
53
 
Lenalidomide-dexamethasone ± 
Pembrolizumab 3 NTE NDMM (640*) N - NCT02579863 
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Pomalidomide-dexamethasone 1/2 
Lenalidomide-refractory 
RRMM ≥ 2 prior therapies 
(48) 
Y 65% Badros et al54 
Pomalidomide-dexamethasone ± 
Pembrolizumab 3 
RRMM ≥ 2 prior therapies 
(300*) N - NCT02576977 
PD-L1 
Durvalumab 
Arm A: durvalumab + lenalidomide-
dexamethasone in high risk NTE 
NDMM 
Arm B: durvalumab + lenalidomide-
dexamethasone in standard risk NTE 
NDMM 
Arm C: durvalumab +lenalidomide 
maintentance for high risk post-ASCT 
NDMM 
1b NDMM (138*) N - NCT02685826 
Arm A: durvalumab monotherapy 
Arm B: durvalumab + pomalidomide 
Arm C: durvalumab + pomalidomide-
dexamethasone 
1b RRMM ≥ 2 prior therapies (138*) N - NCT02616640 
Atezolizumab 
- 1 Solid and hematologic tumors (na) N - NCT01375842 
Arm A: monotherapy 
Arm B: atezolizumab-lenalidomide 
Arm C: atezolizumab post-ASCT 
Arm D: atezolizumab + daratumumab 
Arm E: atezolizumab + daratumumab 
+ lenalidomide 
Arm F: atezolizumab + daratumumab 
+ pomalidomide 
1 
Arm A-E: RRMM ≥ 1 but 
≤ 3 prior therapies 
 
Arm F: RRMM ≥ 3 prior 
therapies 
 
(214*) 
N - NCT02431208 
KIRs 
IPH2101 
- 1 RRMM ≥ 1 prior therapies (32) Y 0 Benson et al
80
 
- 2 Smoldering MM (9) Y 0 Korde et al60 
Lenalidomide 1 RRMM 1 or 2 prior therapies (15) Y 33% Benson et al
81
 
Lirilumab Arm A: Lirilumab + Elotuzumab Arm B: Urelumab + Lirilumab 1 
Post-ASCT RRMM 
achieving at least a very N - NCT02252263 
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good partial response 
Legend. ORR: Overall Response Rate (≥ partial response); NCT: clinicaltrials.gov identification number; Y: Yes; N: No; *:expected number of MM patients 
enrolled; 1: data regarding MM patients; SCT: stem cell transplantation; ASCT: autologous SCT; na: not available; TE: transplant eligible; NTE: transplant 
ineligible; RRMM: relapsed and/or refractory MM; NDMM: newly diagnosed MM. 
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Table 2. Similarities and differences between CTLA-4 and PD1 molecules.37,43,82,83 
 
CTLA4 PD1 
Knock-out mouse: lymphoproliferative phenotype predominant Knock-out mouse: autoimmune phenotype predominant 
Expressed by T-Cells Expressed by many immune cell subsets 
Reduce T-cell proliferation, cytokine production and effector function. Reduce T-cell proliferation, cytokine production and effector function. 
Expression level on T cells affected by intensity and duration of TCR signaling Expression level on T cells affected by intensity and duration of TCR signaling 
Ligand CD28 expressed by professional immune cells Ligand PD-L1 expressed by immune and nonimmune cells (e.g. endothelium, tumor cells) 
No data on CD28 expression and response correlation PD-L1 expression on tumor cells may predict clinical responses 
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Figure 1. Potential immune-oncologic approaches in MM with key targets and effectors. 
 
Legend. TCR: t-cell receptor; CAR: chimeric antigen receptor; PD1: programmed cell death protein1; PDL1: programmed cell death ligand 1; CTLA4: cytotoxic 
T-lymphocyte-associated antigen 4; KIRs: Killer-cell immunoglobulin-like receptors; MHC I: histocompatibility class I molecules; CS1: Signaling lymphocytic 
activation molecule F7 or SLAMF7; BCMA: B-cell maturation antigen; B7.1: Activation B7-1 Antigen or CD80. 
 
